Rush is the only academic medical center in the Chicago area involved in the trial and one of only 50 sites in the U.S. and the world.
The randomized, multinational clinical research trial may determine if repairing a PFO using this device, also known as the GORE HELEX Septal Occluder, is more effective in preventing strokes than medical management alone. The U.S. Food and Drug Administration (FDA) recently granted approval to use the device for PFO closures. It is currently approved by the FDA for the treatment of atrial septal defects (ASDs), a congenital heart defect found in young children.
Latest Articles
Rush is the only academic medical center in the Chicago area involved in the trial and one of only 50 sites in the U.S. and the world. The randomized,...
